tirzepatide fda news - Search News

tirzepatide, FDA

FDA says tirzepatide shortage is over after taking a second look

The FDA said Thursday it’s standing by its earlier decision that the shortage of tirzepatide — the active ingredient in Eli Lilly’s diabetes and weight loss drugs Mounjaro and Zepbound — is over.

JD Supra · 2h

GLP-1 Drugs: FDA “Re-Confirms” Decision Removing Tirzepatide from the Drug Shortage List

On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a Declaratory Order reevaluating and re-confirming that the tirzepatide

UPI News on MSN · 3d

FDA says shortage of GLP-1 drug tirzepatide is over

The U.S. Food and Drug Administration reissued a decision first made by the agency in October that a shortage of the diabetes/weight-loss med tirzepatide is over.

Becker's Hospital Review · 4d

FDA reaffirms end of Mounjaro shortage

FDA resolves two-year shortage of Mounjaro and Zepbound after pushback from compounding pharmacies. Lawsuit filed, but agency reaffirms decision.

The Hill · 4d

FDA keeps Mounjaro off shortage list after reevaluation

The Food and Drug Administration (FDA) has reaffirmed that Mounjaro and Zepbound are no longer in shortage following a reevaluation of its decision to remove it from federal drug shortage list

obstructive sleep apnea, FDA and Zepbound

emjreviews.com · 2h

Eli Lilly’s tirzepatide wins FDA nod for sleep apnea

Eli Lilly’s weight-loss drug tirzepatide has become the first drug for obstructive sleep apnea, a common but serious sleep disorder.

ConsumerAffairs · 15h

FDA approves Zepbound as a treatment for obstructive sleep apnea

Zepbound is Eli Lilly’s weight loss drug. Now, it is also a drug to treat obstructive sleep apnea (OSA).The U.S. Food and Drug Administration has appro

U.S. News & World Report · 4h

GLP-1 Zepbound Is Approved As First Drug For Sleep Apnea

FDA stated that Zepbound, part of the GLP-1 receptor agonist medicines that include Ozempic, was cleared to treat moderate to severe OSA in individuals with obesity. According to drugmaker Eli Lilly,

FDA: Weight loss drug Zepbound, diabetes drug Mounjaro no longer in shortage

Consumers who take copies of the weight loss drug Zepbound and diabetes drug Mounjaro will need to find a new source for ...

STAT3d

FDA confirms shortage of weight loss drug tirzepatide is over, gives compounders a grace period

The FDA on Thursday confirmed that a shortage of Eli Lilly’s obesity drug tirzepatide has been resolved, a move that will put ...

MedPage Today3d

FDA Says Compounded Tirzepatide Must Exit the Market

Approved in 2022 for type 2 diabetes and in 2023 for chronic weight management along with diet and exercise, tirzepatide is ...

FiercePharma3d

FDA reaffirms decision to erase Eli Lilly's tirzepatide from shortage list, halting future flow of knockoffs

The FDA has doubled down on its decision to remove Eli Lilly’s tirzepatide from its list of products that are in shortage. | ...

HME News2h

FDA approves GLP-1 for OSA

The U.S. Food and Drug Administration announced Dec. 20 that it has approved Zepbound (tirzepatide) for the treatment of moderate to severe sleep apnea in adults with obesity to be used ...

The FDA says the Zepbound shortage is over. That's rattling the weight loss industry

The U.S. Food and Drug Administration announced Thursday that the shortage of tirzepatide — the active ingredient in Eli ...

STAT3d

Is a contrarian leader good for the FDA?

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

tirzepatide, FDA

obstructive sleep apnea, FDA and Zepbound

Related topics